Free Trial
NASDAQ:ALBT

Avalon GloboCare 5/11/2026 Earnings Report

Avalon GloboCare logo
$0.34 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$0.34 +0.00 (+0.06%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Avalon GloboCare EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avalon GloboCare Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Avalon GloboCare Earnings Headlines

From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
Avalon GloboCare Corp.
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:ALBT) is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products.

The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs.

Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.

View Avalon GloboCare Profile